Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
Clinical trial NCT03134456 · COMPLETED
Trial details
- NCT number
- NCT03134456
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-14
- Primary completion
- 2019-07-08
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.